Interpace Biosciences (OTCMKTS:IDXG) Issues Earnings Results

Interpace Biosciences (OTCMKTS:IDXG – Get Free Report) issued its quarterly earnings results on Monday. The business services provider reported ($0.26) earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $10.37 million for the quarter. Interpace Biosciences had a net margin of 67.64% and a return on equity of 145.40%.

Interpace Biosciences Trading Down 8.6%

OTCMKTS:IDXG traded down $0.52 during mid-day trading on Wednesday, reaching $5.48. 1,600 shares of the stock were exchanged, compared to its average volume of 1,755. The business has a fifty day moving average price of $6.40 and a 200 day moving average price of $8.05. Interpace Biosciences has a 1-year low of $4.95 and a 1-year high of $7.45. The firm has a market capitalization of $30.37 million, a PE ratio of 13.70 and a beta of 0.67.

Interpace Biosciences Company Profile

(Get Free Report)

Interpace Biosciences is a molecular diagnostics company that develops and provides tests to help clinicians assess cancer risk and guide treatment decisions. Its services combine molecular analysis with pathology and related diagnostic expertise. The company’s tests focus on conditions including pancreatic cysts and thyroid nodules. Its offerings have included PancraGEN for pancreatic cyst assessment, as well as ThyGeNEXT and ThyraMIR for evaluating thyroid nodules. Interpace has also offered molecular testing for gastrointestinal cancers.

Read More

Earnings History for Interpace Biosciences (OTCMKTS:IDXG)

Receive News & Ratings for Interpace Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.